- Home
- BFST vs ZYME Comparison
BFST vs ZYME Comparison
Compare BFST & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- ZYME
- Stock Information
- Founded
- BFST 2006
- ZYME 2003
- Country
- BFST United States
- ZYME United States
- Employees
- BFST N/A
- ZYME N/A
- Industry
- BFST Major Banks
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- ZYME Health Care
- Exchange
- BFST Nasdaq
- ZYME Nasdaq
- Market Cap
- BFST 724.9M
- ZYME 867.6M
- IPO Year
- BFST 2018
- ZYME 2017
- Fundamental
- Price
- BFST $25.31
- ZYME $12.41
- Analyst Decision
- BFST Buy
- ZYME Buy
- Analyst Count
- BFST 2
- ZYME 7
- Target Price
- BFST $30.00
- ZYME $19.50
- AVG Volume (30 Days)
- BFST 119.3K
- ZYME 515.2K
- Earning Date
- BFST 07-24-2025
- ZYME 07-31-2025
- Dividend Yield
- BFST 2.27%
- ZYME N/A
- EPS Growth
- BFST N/A
- ZYME N/A
- EPS
- BFST 2.43
- ZYME N/A
- Revenue
- BFST $276,739,000.00
- ZYME $93,384,000.00
- Revenue This Year
- BFST $25.40
- ZYME $44.71
- Revenue Next Year
- BFST $5.33
- ZYME $34.57
- P/E Ratio
- BFST $10.14
- ZYME N/A
- Revenue Growth
- BFST 11.75
- ZYME 85.05
- 52 Week Low
- BFST $20.07
- ZYME $8.32
- 52 Week High
- BFST $30.30
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- BFST 61.01
- ZYME 50.00
- Support Level
- BFST $23.65
- ZYME $12.17
- Resistance Level
- BFST $24.99
- ZYME $12.79
- Average True Range (ATR)
- BFST 0.55
- ZYME 0.47
- MACD
- BFST 0.14
- ZYME -0.04
- Stochastic Oscillator
- BFST 87.07
- ZYME 21.65
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.